MNPR drops as short-term selling pressure persists

Traders Union
All News
Stocks
Monopar Therapeutics slides 5.31% today

Highlights

Monopar Therapeutics named Jeffrey D. Kent, M.D., as Executive Vice President and Head of Medical Affairs, starting September 1, 2026.
The appointment supports Monopar Therapeutics preparations for a potential FDA approval of ALXN1840 in Wilson disease.
Shares of Monopar stock fell 5.31% to $117.65, trading with high intraday volatility and expected to range between $110.07 and $125.23 in the coming days.

Leadership expansion as regulatory push shapes sentiment under selling pressure

Monopar Therapeutics appointed Jeffrey D. Kent, M.D., as Executive Vice President and Head of Medical Affairs, with his tenure set to begin on September 1, 2026, according to Rttnews. This appointment is aimed at enhancing the company’s leadership capacity as it prepares for a potential U.S. FDA approval of ALXN1840 in Wilson disease, with Dr. Kent’s experience expected to guide regulatory strategy and medical outreach. The move reflects ongoing corporate preparations for regulatory milestones, though price action has remained under broader selling pressure.

Technical divergence as near-term resistance holds and momentum splits

MNPR is trading below its MA-20, while remaining above its MA-50 and well above the long-term MA-200 level. The Ichimoku Kijun line is positioned at $117.935 and serves as immediate resistance. MACD shows strong buy momentum, whereas ADX is neutral, indicating an absence of trend direction. RSI displays a sell bias and Stochastic RSI points to oversold conditions. Both CCI and Awesome Oscillator are neutral, and Bull/Bear Power signals seller dominance during the trading session.

Upward probability increases as volatility band defines trading risks

Over the next few sessions, the expected trading range for MNPR is $110.07 to $125.23, reflecting a typical volatility band relative to current levels. There is a 63% probability of an upward move, making further downward action less likely. A steady scenario would see MNPR remaining within this band; a bullish swing would require clearing resistance at $117.935, while sustained weakness could push the price below support at $110.07.

Anton Kharitonov, expert at Traders Union, notes that MNPR is under short-term technical pressure, despite signs of strengthening management ahead of regulatory milestones. He sees momentum indicators mixed, with sell signals dominating intraday and only isolated evidence of buyer interest. The recent appointment signals preparation for FDA review but has not shifted sentiment in the face of persistent selling. "Unless MNPR clears resistance at $117.935, I remain cautious given the lack of a clear upside catalyst and prevailing technical weakness."

Earlier, analysts noted that Monopar Therapeutics was exhibiting strong bullish momentum while cautioning that overbought technical conditions could prompt a period of consolidation. The current session confirms a shift toward short-term selling pressure, with a pivotal area to monitor now being whether MNPR can reclaim and hold above its MA-20 to shift momentum back in favor of buyers.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.